BlueSpruce Investments LP Decreases Position in Zoetis Inc. $ZTS

BlueSpruce Investments LP lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 99.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,429 shares of the company’s stock after selling 747,922 shares during the period. Zoetis accounts for approximately 0.0% of BlueSpruce Investments LP’s portfolio, making the stock its 21st largest holding. BlueSpruce Investments LP’s holdings in Zoetis were worth $648,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. North Star Asset Management Inc. grew its holdings in Zoetis by 4.9% in the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after purchasing an additional 67 shares during the period. Bank of Nova Scotia Trust Co. increased its holdings in Zoetis by 4.6% in the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock valued at $264,000 after purchasing an additional 74 shares in the last quarter. Summit Place Financial Advisors LLC raised its holdings in shares of Zoetis by 0.4% during the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after buying an additional 76 shares during the period. First County Bank CT raised its stake in shares of Zoetis by 5.4% during the third quarter. First County Bank CT now owns 1,535 shares of the company’s stock valued at $225,000 after purchasing an additional 79 shares during the period. Finally, CWA Asset Management Group LLC increased its stake in Zoetis by 1.1% during the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock worth $1,059,000 after buying an additional 80 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.1%

Shares of NYSE ZTS opened at $115.62 on Friday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The stock’s 50 day moving average price is $125.34 and its two-hundred day moving average price is $131.75. Zoetis Inc. has a 52-week low of $114.47 and a 52-week high of $172.23. The stock has a market capitalization of $48.81 billion, a P/E ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s payout ratio is presently 35.22%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ZTS shares. Piper Sandler restated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. UBS Group set a $136.00 target price on Zoetis in a research report on Thursday, January 29th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, HSBC set a $140.00 price target on shares of Zoetis in a research note on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.